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Abstract
Objectives: Recent clinical trials suggest an LDL-independent superiority of intensive statin therapy in reducing target
vessel revascularization and peri-procedural myocardial infarctions in patients who undergo percutaneous coronary
interventions (PCI). While animal studies demonstrate that statins mobilize endothelial progenitor cells (EPCs) which can
enhance arterial repair and attenuate neointimal formation, the precise explanation for the clinical PCI benefits of high dose
statin therapy remain elusive. Thus we serially assessed patients undergoing PCI to test the hypothesis that high dose
Atorvastatin therapy initiated prior to PCI mobilizes EPCs that may be capable of enhancing arterial repair.
Methods and Results: Statin naı ¨ve male patients undergoing angiography for stent placement were randomized to
standard therapy without Atorvastatin (n=10) or treatment with Atorvastatin 80 mg (n=10) beginning three days prior to
stent implantation. EPCs were defined by flow cytometry (e.g., surface marker profile of CD45dim/34+/133+/117+). As well,
we also enumerated cultured angiogenic cells (CACs) by standard in vitro culture assay. While EPC levels did not fluctuate
over time for the patients free of Atorvastatin, there was a 3.5-fold increase in EPC levels with high dose Atorvastatin
beginning within 3 days of the first dose (and immediately pre-PCI) which persisted at 4 and 24 hours post-PCI (p,0.05).
There was a similar rise in CAC levels as assessed by in vitro culture. CACs cultured in the presence of Atorvastatin failed to
show augmented survival or VEGF secretion but displayed a 2-fold increase in adhesion to stent struts (p,0.05).
Conclusions: High dose Atorvastatin therapy pre-PCI improves EPC number and CAC number and function in humans
which may in part explain the benefit in clinical outcomes seen in patients undergoing coronary interventions.
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Introduction
Percutaneous coronary intervention (PCI) is the preferred
revascularization strategy for patients with coronary artery
disease. Recent developments with drug eluting stents (DESs)
have reduced the need for revascularization compared to
balloon angioplasty and bare metal stents (BMSs) resulting in
less need for repeat revascularization. Current strategies for
reducing in-stent neointima formation commonly exploit the
anti-proliferative and anti-inflammatory effects of paclitaxel and
sirolimus. Unfortunately, the negative effect of these drugs on
stent strut endothelialization may be dire due to an increased
risk of sudden stent thrombosis.[1] Clinical and animal studies
suggest a role for circulating endothelial progenitor cells (EPCs)
in reconstituting the endothelium and reducing neointima
formation following injury. [2] Indeed, the paucity and/or
impaired functional capacity of EPCs are inversely associated
with cardiac risk factors, cardiovascular outcomes and restenosis
rates.[3,4] In animal studies, interventions that enhance
mobilization of EPCs such as G-CSF, HMG-CoA reductase
inhibitors (also known as ‘‘statins’’) or estrogens uniformly result
in improved endothelialization and diminished neointimal
formation.[5–7]
Statins induce a robust mobilization of murine CD117+/Sca-1+
progenitor cells and EPCs via the PI3K/Akt pathways and
enhance endothelialization of injured vessels thereby leading to
attenuation of neointimal formation.[7–10] Moreover, recent
clinical trials show an LDL-independent superiority of intensive
compared to moderate statin therapy in reducing target vessel
revascularization in patients who undergo PCI for acute coronary
syndromes.[11] However, the precise explanation for the clinical
advantage of high dose statin therapy with PCI remains elusive.
Therefore, we performed serial assessments of patients undergoing
PCI to test the hypothesis that high dose Atorvastatin (80 mg)
therapy initiated prior to PCI mobilizes EPCs that may be capable
of enhancing arterial repair.
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Ethics Statement
The protocol was approved by the University of Ottawa Heart
Institute Research Ethics Committee (protocol #:04-122) and
Health Canada. All patients gave written informed consent and
research was conducted according to the principles expressed in
the Declaration of Helsinki.
Patients and Protocol
Our study was designed to longitudinally assess the effects of
statin therapy on patients undergoing PCI with stent deployment.
Patient inclusion criteria included the following: .18 years of age,
no treatment with a HMG-Co-A reducatse inhibitor in the
preceding 3 months, availability for a 14 day follow-up blood test,
and the patient had to be scheduled for a coronary angiogram with
possible ad hoc PCI and stent implantation. Furthermore, to
exclude the confounding factor of estrogens in pre- and post-
menopausal women, only males were included in the study.
Exclusion criteria included an unstable condition requiring urgent
cardiac catheterization, hematological malignancy, therapy with
G-CSF or GM-CSF, or previous statin intolerance.
Patients were randomized to Atorvastatin 80 mg per day or
medical therapy without a statin beginning three days prior to a
scheduled angiogram. Baseline laboratory tests included a
complete blood count, HbA1C level, fasting lipid profile, C-
reactive protein (CRP), erythrocyte sedimentation rate (ESR),
assessment of EPCs by flow cytometry (CD45dim/CD34+/
CD133+/CD117+), and enumeration of cultured angiogenic cells
(CACs). All of the aforementioned tests were repeated at time of
arterial catheterization (i.e., at outset of coronary angiographic
procedure and prior to commencement of an ad hoc PCI), 4 hours
post PCI, 24 hours post PCI, and at 14-day follow-up. In addition,
troponin-T (TnT) and creatine kinase-MB (CKMB) fractions were
measured pre-procedural and at the 4 and 24 hour follow-up time
points to identify peri-procedural myocardial infarctions (MI) as
defined by a.3x rise above the upper limit of normal.
Statin naı ¨ve patients were randomized in blocks of 6; however,
after the first 18 patients had been enrolled 8 patients had
completed the protocol in the non-statin control arm and only 2
patients had completed the protocol in the statin arm. In the statin
arm of the study the following patients did not complete the
protocol: 2 patients without CAD, 3 patients who were deemed
non-revascularizable and 2 patients who were referred for
coronary artery bypass grafting. Therefore, the statin randomiza-
tion scheme was redone for a total of 40 patients to be enrolled in
order to yield 10 patients completing each study arm. As well, 11
healthy controls without clinically evidence of CAD were recruited
for comparison of baseline EPC and CAC levels. Four patients
initially randomized in the trial whom were found to have normal
coronaries were combined with the 11 healthy individuals for a
total of 15 healthy controls.
EPC and CAC quantification
EPCs were assessed by flow-cytometry and CACs by in vitro
culture assay. All blood samples for EPC enumeration were drawn
by venous or arterial puncture then anticoagulated with EDTA.
EPCs were enumerated using a standardized flow cytometric
protocol. Briefly, five-color flow cytometry was performed for the
markers CD34 (clone 581, fluorochrome PC7), CD45 (clone J133,
fluorochrome ECD), CD133 (clone AS133, fluorochrome PE), and
CD117 (clone 104D2D1, fluorochrome PC5), and CD49e (clone
SAM1, fluorochrome FITC). Antibodies were purchased from
Beckman Coulter and studies performed on a Beckman Coulter
Cytomics FC 500 cytometer. Red blood cell lysis was performed
using IO Test 3 solution (Beckman Coulter) and samples were
then incubated with appropriate dilutions of antibodies. As isotype
controls are known to mask rare cell populations,[12] none were
used in this analysis, and baseline fluorescence was determined
using unstained cells. All reported EPC counts were adjusted for
total white blood cell counts as determined by standard complete
blood counts in our regional hematology laboratory.
We prospectively defined EPCs as CD45dim/CD34+/CD133+/
CD117+. Recognizing that circulating EPCs have historically
been defined by CD34+/KDR+[13,14] preliminary studies were
performed looking at expression of KDR and CD117 cells which
demonstrated that virtually all cells expressing KDR also co-
expressed CD117. Thus, KDR was not included in the final panel
of markers. It is important to note that human CD45-/CD117+/
KDR+ cells can incorporate into the coronary vasculature and
display clonal proliferative potential, suggesting an EPC pheno-
type.[13,15] Moreover, CD45-/CD117+ of cardiovascular origin
have recently been shown to co-express CD31, CD34, CXCR4,
and KDR.[13]
While initially termed EPCs, CACs are now recognized to be
involved in regulating angiogenesis without directly contributing to
post-natal vasculogenesis and thus are now termed cultured
angiogenic cells. CAC have been extensively described in the
literature and are known to be inversely associated with risk factors
for CAD.[16]Indeed, numerous studies have highlighted the
important roles CACs play in regulating the angiogenic and tissue
remodeling response in various disease states.[17–19] The
methodology used for the CAC culture assay is previously
described.[20–23] Briefly, peripheral blood mononuclear cells
(5610
6) isolated by Ficoll centrifugation were cultured in EGM-2
media (Cambrex) before being dispersed on fibronectin coated
plates. Cells were washed at 4 days and adherent cells were
maintained for 7 days prior to enumeration. For the task of
enumeration, CACs were defined as cells dually positive for
AcLDL uptake and ulex europeus agglutinin I (UEAI) binding. While
uptake of AcLDL and binding of UEAI may non-specifically
identify myeloid and epithelial cells,[13,24] we have previously
demonstrated the capacity of these cells to facilitate vascular repair
in vivo[19] and others have demonstrated expression of the
endothelial markers KDR, CD31, vWF, and eNOS.[13] DiI-
AcLDL (2.5 mg/ml, Molecular Probes) was incubated with
cultured CACs for 1 hour in a cell incubator. Subsequently, cells
were washed and fixed with Cytofix Buffer (BD) and incubated
with FITC-UEAI (5 mg/ml, Sigma) for 30 minutes. Plates of cells
were again washed then incubated with a DAPI nuclear
counterstain before a coverslip was applied to the well and double
positive cells (CAC) were counted in 6 random high power fields
(6200 magnification).
CAC Functional assays
The effects of Atorvastatin on CAC survival, VEGF secretion,
and adherence to bare metal stent struts were tested using 7 day
old CACs. The culture media for Atorvastatin treated cells was
supplemented with 0.1 mmol/L of Atorvastatin (Pfizer) or DMSO
(vehicle) consistent with a previously published study.[25]
For cell survival, six high-power fields were enumerated and the
media was changed every 4 days. Data are expressed as a
percentage of initial cells. Secretion of VEGF was measured using
a VEGF ELISA kit (R&D systems). CACs were plated in equal
numbers and cultured in VEGF free EMG-2 media for 24 hours.
Subsequently, 200 mL of the supernatant was isolated and used in
the ELISA assay. Stent adhesion studies were performed using
BMSs (Medtronic Micro-Driver) that were cut, flattened, and fixed
Stents, Statins, and Progenitor Cells
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that the stent strut projected above the collagen base as previously
described.[22] Seven day old CACs (2610
5) were resuspended
and cultured for 48 hours. Cells were stained with DAPI, fixed
and attached cells enumerated.
Q-PCR for alpha integrins was performed as previously
described.[19] Briefly, PCR was performed utilizing an annealing
temperature of 56 degrees Celsius. The Qiagen QuantiTect SYBR
PCR system was utilized as per manufacturer instructions. All
experiments were performed using a Roche LightCycler 480. The
following primer combinations were utilized: GAPDHfwd (CG-









a-5fwd (TGCCTGAGTCCTCCCAATTTCAGA), a-5rev (ACA-
TGAGGACCAAGGTGGTAAGCA).
Statistical Analysis
For statistical procedures, a p-value of ,0.05 was considered
significant. All continuous variables are expressed as means +/2
standard error of the mean (SEM). Data normality was tested
using the Kolmogorov-Smirnov test. Two way comparisons were
done by t test and the interaction between statin therapy and PCI
by two-way repeated measures analysis of variance with pairwise
comparisons done with Bonferroni post hoc testing. Alternatively,
for nonparametric statistical testing a Mann-Whitney Rank Sum
test was used. All statistical procedures were performed using the
Sigma Stat 3.5 statistical package.
Results
Clinical and laboratory profiles
In each group 10 patients completed the protocol receiving at
least one stent. In total, 15 healthy controls were analyzed for
comparison – 4 patients who underwent angiography and had
normal coronary arteries and 11 healthy individuals without
clinical evidence of CAD.
Of the 20 patients completing the protocol, all underwent
successful revascularization with deployment of at least one stent.
Baseline characteristics were similar between the treatment groups
including the number and types of stents (DES vs BMS) used
(Table 1). In terms of adverse events, only one post-PCI MI was
recorded in the statin group and one patient in the control arm
was withdrawn from the study after having a stroke related to the
catheterization procedure. At time of discharge patients received
evidence-based medical therapy for CAD (eg. aspirin, clopidogrel,
b-blocker, and an angiotensin converting enzyme inhibitor or
angiotensin II receptor blocker, Table 1). All patients that
underwent PCI completed follow-up and no other adverse events
were noted to 14 days.
In terms of baseline laboratory values, total white count,
HbA1C levels, C-reactive protein levels, and cholesterol profiles
were similar at baseline between the groups. However, at follow-
up the total white count in the statin arm was higher
than controls (8.8+/21.4 vs 6.3+/21.9 10
9 cells/L, p,0.01,
Table 2). Furthermore, as expected both total and LDL
cholesterol levels were lower in the statin arm (2.9+/21.0 vs.
4.6+/21.0 and 1.3+/20.7 vs. 3.0+/21.0 mmol/L respectively,
p,0.01).
Effect of statin therapy on circulating EPC and CAC levels
a) Baseline Flow Characteristics. CD45dim EPC were
enumerated at baseline in a total of 47 individuals, 32 with CAD
and 15 healthy controls (Figure 1A). While healthy controls had
nearly three fold more EPC than CAD patients the difference did
not reach significance (12.7+/22.7 vs 5.4+/20.6 cells/mL,
p=0.07). Patients who had been referred for angiography after
presenting with an acute coronary syndrome (ACS) in the previous
14 days did not have more EPC at baseline than non-ACS patients
(5.0+/21.0 vs. 5.6+/20.6 cells/mL, p.0.05).
b) Serial Flow Cytometric Assessment of Cell
Profiles. When looking at the effects of PCI on mobilization
of EPC we compared the abundance of this cell type at the
following intervals: three days prior to catheterization, pre-
catheterization, 4 hrs, 24 hrs and 14 days. While EPC levels did
not fluctuate over time for the patients who did not receive
Atorvastatin, there was a 3.5-fold increase in EPC levels with high
dose Atorvastatin within 3 days of the first dose (immediately pre-
Table 1. Patient Characteristics.
Control Group Statin Group Healthy
(n=10) (n=10) (n=15)
Characteristics
Males 10 (100%) 10 (100%) 15 (100%)
Age in years (SD) 59.5 (6.9) 63.0 (10.5) 34.4 (12.6)
CCS class I-II 5 (50%) 7 (70%) 0 (0%)
CCS class III-IV 5 (50%) 3 (30%) 0 (0%)
Previous PCI 2 (20%) 0 (0%) 0 (0%)
Cardiac Risk Factors
Hypertension 3 (30%) 4 (40%) 0(0%)
Smoking 2 (20%) 2 (20%) 1 (6.7%)
Family History 3 (30%) 3 (30%) 2 (13.3%)
Hyperlipidemia 3 (30%) 3 (30%) 1 (6.7%)
Diabetes mellitus 2 (20%) 0 (0%) 0 (0%)
eGFR (SEM) 86 (7) 75 (6) 107 (9)
Angiogram/PCI
# of stents deployed (SD) 1.2 (0.4) 1.6 (0.8)
Drug-eluting stents used 4 (40%) 5 (50%)
Severe CAD 0(0%) 2 (20%)
Medical Therapy
Clopidogrel 10 (100%) 10 (100%)
Aspirin 10 (100%) 10 (100%)
b-blocker 8 (80%) 9 (90%)
ACEI/ARB 9 (90%) 10 (100%)
Atorvastatin 0 (0%) 10 (100%)
CCS Class – Canadian Cardiovascular Society Angina Class.
PCI – percutaneous coronary intervention.
CAD – coronary artery disease.
MI – myocardial infarction.
ACEI/ARB – angiotensin converting enzyme/angiotensin II receptor blocker.
eGFR – estimated glomerular filtration rate ml/min/1.73 m
2.
SD – standard deviation.
SEM – standard error of the mean.
doi:10.1371/journal.pone.0016413.t001
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was no effect seen on EPC levels caused by PCI (Figure 1B).
Additionally, we serially assessed CD49e expression on circulating
EPCs and found low levels of basal expression and both the
number of CD49e+ cells nor the relative CD49e expression was
effected by statin therapy or PCI (data not shown).
c) In vitro CAC Assessment. CAC were enumerated by
culture assay and yielded similar results to those obtained by flow
cytometry. Baseline CAC levels were 2-fold higher in healthy
controls compared to patients with CAD at baseline (e.g., 38.8+/
22.3 vs. 17.1+/21.5, p,0.01, Figure 2A). Again, there were no
differences in CAC levels between patients with a recent ACS
compared to those with clinically stable symptoms (p,0.05, data
not shown). Interestingly, a significant interaction was seen
between Atorvastatin therapy and PCI when precatheterization,
4 hour and 24 hour levels were assessed (2 way ANOVA:
p=0.006 for Atorvastatin and Time from PCI interaction).
However, in those patients receiving Atorvastatin, there was an
early increase in CAC levels until 24 hours post-PCI followed by a
tapering off effect – although 14 day levels remained
approximately 2-fold higher than baseline (e.g., 4 h: 2.7+/21.5,
24 h: 3.4+/20.6, 14 d: 1.9+/20.3, Figure 2B).
Effect of statin therapy on function of CAC
Statin supplementation of the culture media at a concentration
of 0.1 mM failed to alter survival of CAC in vitro (Figure 3D,
p.0.05). Similarly, secretion of the angiogenic cytokine VEGF
was unaffected by culture in the presence of Atorvastatin in the
culture media (e.g., 28.5+/23.5 vs 32.9+/23.6 ng/mL,
Figure 3C,p .0.05). Finally, CAC adhesion to BMSs was tested
in vitro by co-culture of CAC in the presence of a bare metal
coronary stent immobilized in collagen. After 48 hours in vitro, co-
culture with Atorvastatin augmented CAC attachment to stents by
2-fold compared to cells co-cultured in the absence of Atorvastatin
(e.g., 9.7+/20.9 vs. 4.0+/20.6, n=10, p,0.01, Figure 3A,B).
As integrins are known to be important modulators of CAC
adhesion[19,26] we assayed by RT-qPCR the expression of the
a1-5 subunits of the integrin family and found no significant
regulation of mRNA levels (p.0.05, data not shown).
Discussion
While it is empirically recognized that statins may increase EPC
levels in patients, the temporal course and profile of the cells
mobilized by statins at time of PCI had not previously been
characterized. Nonetheless, patients undergoing the implantation
of stents designed to trap CD34+ cells (e.g., Genous endothelial
progenitor cell capturing stent) are routinely pre-treated with high
dose statin therapy with the hope of augmented circulating EPC
levels.[27] This study is the first attempt to prospectively
randomize patients undergoing stent insertion to high dose statin
therapy and describe in a serial fashion the time course and extent
of EPC and CAC mobilization. Our data demonstrates that 80
milligrams of Atorvastatin per day, beginning three days prior to
PCI, is associated with a mobilization of both EPC and CAC. As
well, this is the first study to enumerate the highly selective
population of CD34+/CD117+ (c-kit) progenitors by flow
cytometry in patients undergoing revascularization. Recently c-
kit has been found to define a population of human coronary
vascular progenitor cells that are capable of regenerating
competent coronary vessels and improving coronary blood
flow.[15] Finally, we demonstrate that statin treatment improves
the functional capacity of CAC, by augmenting attachment to
stent struts using a novel in vitro model. It is important to note that
this increase in EPC adhesion was not due modulation to member
of the integrin family and similar to in vivo observations by
Banerjee et al.,[28] occurred without a change in VEGF levels.
Results from the studies of EPCs and PCI continue to yield
equivocal or discordant results.[29] This likely reflects both the
varying manner in which EPCs are quantified as well as limitations
in study design. For example, the largest study to date was
performed by Inoue et al. who looked at 40 patients undergoing
PCI.[30] They studied both CD34+ cells by flow cytometry and
outgrowth of either endothelial or smooth muscle cells (SMCs)
from PBMCs at multiple time points out to one month post PCI.
They noticed an association between mobilization of CD34+ cells
and outgrowth of SMCs with ISR but by limiting their flow
cytometry to a single marker they most certainly included all early
bone marrow derived cells including hematopoietic progenitors
cells. Mills et al. examinined circulating EPC number and colony
forming unit mobilization in 24 patients undergoing elective
PCI.[31] Similar to our data, they observed a 3-fold increase in
cultured cells in the first 24 hours following PCI with the majority
of their patients being concomitantly treated with statin medica-
tions. Finally, Egan et al.[32] compared 10 patients undergoing
PCI with 13 patients having angiogram only and found that
CXCR4 positive cells were mobilized in response to PCI when
compared to angiography alone. In contrast, our study looked at
multiple time points out to two weeks after PCI in a total of 20
patients between both arms. More importantly, our data is the first
to randomize patients to statin medications and to serially assess
their EPC levels – providing a novel mechanistic link between the
observed clinical outcomes and early statin therapy in patients
undergoing PCI.







WBC (SEM) 7.2 (1.5) 8.0(2.4) 6.9 (1.5) NS
HbA1C 0.052 (0.005) 0.051 (0.003) 0.053 (0.003) NS
C-reactive protein 6.8 (11.4) 8.3 (9.0) 1.9 (1.1) p,0.05
Total cholesterol 5.3 (0.7) 4.8 (1.0) 5.0(1.0) NS
HDL 1.0 (0.3) 1.0 (0.1) 1.2 (0.3) NS
LDL 3.3 (0.6) 2.9 (0.9) 3.3 (1.0) NS
TG 2.1 (1.0) 1.9 (1.2) 1.3 (0.9) p,0.05
Follow-up
WBC 6.3 (1.9) 8.8 (1.4) p,0.01
HbA1C 0.053 (0.001) 0.054 (0.001) NS
C-reactive protein 6.5 (8.2) 21.7 (6.9) NS
Total cholesterol 4.6 (1.0) 2.9 (1.0) p,0.01
HDL 1.0 (0.2) 0.9 (0.2) NS
LDL 3.0 (1.0) 1.3 (0.7) p,0.01
TG 1.6 (0.5) 1.5 (0.7) NS
WBC – white blood cell 10
9 cells/L.
HbA1C – hemoglobin A1C.
HDL – high density lipoprotein mmol/L.
LDL – low density lipoprotein mmol/L.
TG – triglycerides mmol/L.
SEM – standard error of the mean.
doi:10.1371/journal.pone.0016413.t002
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therapy on both initial mobilization and maintenance of EPC
levels has yielded sometimes conflicting results. Vasa and
colleagues first reported an increase in EPCs (CD34+/KDR+)
and CACs out to 28 days in 40 patients with CAD.[33] Most
recently, these results were replicated in a small cohort of patients
initiated on Atorvastatin therapy, yielding a doubling of
CD45dim/CD34+/KDR+ cells at four weeks.[34] While neither
of these studies were randomized or had control groups for
comparison, their results are very similar to those observed in the
current study. Paradoxically, in patients with CAD Hristov et al.
[35] quantified both EPCs and CACs in a large non-randomized
cohort and noted a decrease in EPCs during chronic statin therapy
(especially at higher doses). Similarly, Deschaseaux et al. [36]
derived fewer colony forming units from patients on chronic statin
therapy than a matched cohort, suggesting the initial mobilization
observed may not be sustained over longer periods. However, the
non-randomized nature of these studies and the lack of standard
dosing certainly justifies trepidation in drawing firm conclusions.
Data from large randomized studies of both early and longterm
effects of statin therapy on EPCs is clearly warranted.
Perhaps the most intriguing finding of our study was the early
difference in EPC levels seen with Atorvastatin loading – an effect
that was observed with both flow cytometry and CAC culture
which persisted for at least 24 hours post-PCI. However, by 14
days EPC levels had tapered off somewhat – yet remained elevated
relative to baseline levels. The cause of the diminution of EPCs by
day 14 is unclear, but perhaps suggests that the mobilization of
EPCs by statins is a time-limited, transient effect. Alternatively,
there may be either no further EPCs available to be mobilized or
some other rate-limiting process is preventing EPCs from being
generated and/or mobilized by statins. Interestingly, there was a
noticeable rise in EPC levels in the control arm at 14 days. This
likely in part reflects more aggressive management of patients
atherosclerotic disease and risk factors in patients newly identified
with CAD. For example, smoking cessation has been associated
with and early and robust rise in EPC levels.[37] Similarly
complimentary pharmacotherapy such as angiotensin converting
enzymes[38] or thiazolidinediones (glitazones)[39] are also known
to increase EPC levels. Thus, this late rise in the control patients
most likely represents improved risk factor modification.
It is important to realize that our protocol is similar to those
used in the ARMYDA,[40] ARMYDA-ACS,[41] and the more
recently completed ARMYDA-RECAPTURE[42] studies. Both
ARMYDA and ARMYDA-ACS demonstrated a clear reduction
in peri-procedural myocardial infarctions in statin naı ¨ve patients
undergoing PCI for stable coronary artery disease or acute
coronary syndromes respectively when high dose Atorvastatin
was initiated prior to the procedure. Perhaps more clinically
relevant is the ARMYDA-RECAPTURE study in which the
investigators reloaded patients already on statins with 80 mg of
Atorvastatin and showed reductions in peri-procedural myocar-
Figure 1. Flow cytometric analysis of CD45dimCD34+CD133+CD117+ endothelial progenitor cells (EPC). (A) Sample gating strategy. (B)
EPC levels, expressed at each interval as a ratio to baseline levels (taken three days prior to PCI) for patients receiving and not receiving Atorvastatin
therapy (n=10 per group). * indicates p,0.05.
doi:10.1371/journal.pone.0016413.g001
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PLoS ONE | www.plosone.org 5 January 2011 | Volume 6 | Issue 1 | e16413Figure 2. In vitro assessment of cultured angiogenic cells (CAC). (A) Comparison of baseline CAC levels in patients with CAD (n=32) vs.
healthy controls (non-CAD). (B) CAC levels expressed at each interval as a ratio to baseline levels (taken three days prior to the procedure) for patients
receiving and not receiving Atorvastatin therapy (n=10 per group). * indicates p,0.05, # indicates p,0.01.
doi:10.1371/journal.pone.0016413.g002
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IT study that compared the frequency of major adverse cardiac
events in patients undergoing PCI and treated with either
moderate (Pravastatin 40 mg/day) or intensive (Atorvastatin
80 mg/day) statin therapy there was a clear cut advantage for the
patients treated in the intensive therapy arm.[11] For example,
the primary composite end point (death from any cause,
myocardial infarction, documented unstable angina requiring
hospitalization and revascularization at least 30 days after
randomization, and stroke) showed a 22% relative risk reduction
with intensive statin therapy (p=0.001) Moreover, the intensive
statin therapy reduced target vessel revascularization (p,0.001) –
an effect that persisted (p=0.015) after adjusting for 30-day on
treatment serum LDL-C and CRP concentrations. Clearly the
rapid clinical benefits seen in these studies involving intensive
statin therapy suggests a mechanism of action that is independent
of LDL-lowering. Given the similarities of these studies to our
current protocol, it is attractive to hypothesize that the benefit of
acute Atorvastatin loading prior to PCI may in part be derived
from the off-target effects of statins on EPC mobilization and
function.
Certainly, our study is not without limitations. For example,
given the widespread use of statins in patients with risk factors for
established CAD, it proved difficult to recruit statin naı ¨ve patients
for this study. Therefore, while our sample size allows us to
confidentially address questions specific to serial changes in EPCs,
it lacks sufficient power to address the relationship between EPC
mobilization profiles and clinical outcomes (e.g., ISR or peri-
procedural infarctions). Furthermore, given the relatively small
patient population, it is unclear if this observation is applicable in
populations in whom statin therapy has failed to show a benefit –
such as patients on hemodialysis.[43,44]
Figure 3. Effect of statin on cultured angiogenic cell (CAC) function in vitro. (A) Atorvastatin supplementation of the media (0.1 mM). Statin
treatment improves CAC attachment to bare metal stent struts in vitro (n=10). * indicates p,0.01. (B) Representative photos showing DAPI nuclear
staining of CAC attachment to stent struts. (C) Atorvastatin supplementation of the media at 0.1 mM does not effect VEGF secretion by EPCs (n=6,
p.0.05). (D) Statin does not ameliorate survival of CACs in culture (n=6, p.0.05).
doi:10.1371/journal.pone.0016413.g003
Stents, Statins, and Progenitor Cells
PLoS ONE | www.plosone.org 7 January 2011 | Volume 6 | Issue 1 | e16413In summary, our data demonstrate early benefit of statin
therapy on EPC number and CAC number and function in
humans undergoing PCI. Studies aimed to understand mecha-
nisms by which EPCs are mobilized during PCI and the potential
benefits that these cells confer will likely provide novel targets and
therapies for improving clinical outcomes in patients undergoing
revascularization.
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